Phaseline

Targets › CD52

CD52 (CAMPATH-1 antigen): drug programs, companies and trials

2 programs from 2 companies in 5 trials: 4 Phase 1, 1 Phase 2; Oncology, Hematology; next expected readout Dec 2027.

May play a role in carrying and orienting carbohydrate, as well as having a more specific role. (UniProt, P31358)

Open in Phaseline: the race on CD52, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
National Heart, Lung, and Blood Institute (NHLBI)Alemtuzumab
CAMPATH-1 antigen inhibitor
CD52Phase 2Sickle Cell Disease; Sickle Cell Anemia; Congenital Hemolytic AnemiaDec 2027
Allogene TherapeuticsALLO-647
Monoclonal antibody targeting CD52
CD52Phase 1Advanced/Metastatic Clear Cell Renal Cell CarcinomaJan 2030

Conditions

Sickle Cell Disease (2) Advanced/Metastatic Clear Cell Renal Cell Carcinoma (1) Sickle Cell Anemia (1) Congenital Hemolytic Anemia (1)

Modalities

mixed (2)

Companies

Allogene Therapeutics (1) National Heart, Lung, and Blood Institute (NHLBI) (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.